Information Provided By: 
Fly News Breaks for September 25, 2017
JAZZ
Sep 25, 2017 | 07:52 EDT
UBS analyst Marc Goodman lowered his sales estimates for Jazz Pharmaceuticals' Erwinase and Defiteleo as recent sales data indicated both were down for the month of August. As a result, he believes Q3 consensus may be too high. However, the recent weakness in the stock already reflects the concerns surrounding both drugs, said Goodman, who maintained his Buy rating but lowered his price target on Jazz to $172 from $175.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
